Loyola offers new, nonsurgical treatment for Dupuytren's contracture

Loyola University Health System is among the first centers to offer a new, nonsurgical treatment for Dupuytren's contracture, a debilitating condition that curls fingers toward the palm.

Dupuytren's contracture affects one or more fingers, usually the little finger and ring finger. Growth of a cord of tissue under the skin causes the finger to bend inward so that the finger can not be straightened.

The traditional treatment is outpatient surgery to remove the tissue, said Loyola hand surgeon Dr. Randy Bindra. The patient has stitches for 10 to 14 days and needs to do physical therapy. It takes one to three months before the fingers become fully flexible.

The new drug is Xiaflex® (collagenase clostridium histolyticum). In an outpatient clinic, a doctor injects the drug into a Dupuytren's cord that is causing the finger to bend. The drug contains enzymes that break down collagen, one of the main components of the cord.

The patient returns to the clinic the next day, and the physician gently extends the finger to break the cord. "The patient feels a pop and the finger opens up," Bindra said. No physical therapy is needed.

The treatment worked well for James Santo, 83, of Chicago. Santo had Dupuytren's contracture on the little finger of his right hand. His finger curled so much the tip touched the palm of his hand.

Bindra administered one injection. Santo said it felt like an ordinary shot, and he experienced no pain afterward.

Santo can now extend his finger until it is nearly straight. "It's normal now," he said.

A study of 306 Dupuytren's contracture patients found that 64 percent had a straight or nearly straight hand after one to three injections of the drug, compared with 7 percent who received a placebo. The Food and Drug Administration, which approved the drug, called it "an important advance in the management of this disabling condition."

Bindra said the injections must be carefully administered, because the drug can dissolve collagen in healthy skin and tendons. If injected in the wrong spot, the drug can snap a tendon and leave the patient unable to close the finger. As a hand surgeon who has done more than 100 surgeries for Dupuytren's contracture, Bindra knows exactly where to inject the drug.

The Food and Drug Administration said the drug should be administered only by a health care professional experienced with the anatomy of the hand, because tendon ruptures can occur.

The most common adverse reactions to the drug are fluid build-up, swelling, bleeding and pain in the injected area, the FDA said.

Bindra said the drug does not necessarily cure the condition. In some patients, the abnormal tissue grows back and curls the finger, requiring further treatment.

Dupuytren's contracture often runs in families. It is more common in men, especially in the case of Northern European descent. Other risk factors include increasing age and certain medical conditions, such as diabetes and seizures.

SOURCE Loyola University Health System